Vilon

What is Vilon?

Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid (Lys-Glu, single-letter code: KE). It is one of the two primary active dipeptides isolated from the calf-thymus complex Thymalin by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — the other being the Glu-Trp dipeptide marketed as Thymagen (Thymogen). Within the Khavinson bioregulator framework, Vilon is positioned as a short peptide that supports thymic and immune function, modulates gene expression in lymphocyte and other aging tissues, and contributes to the claimed lifespan-extending and anti-carcinogenic effects attributed to the parent Thymalin complex. The tripeptide Bonothyrk and the tetrapeptide Livagen (Lys-Glu-Asp-Ala) share the same N-terminal Lys-Glu motif, and the Khavinson group treats Vilon as the minimal active fragment underlying that family.

What Vilon Is Investigated For

Vilon (Lys-Glu, KE) is studied within the Khavinson bioregulator system primarily for immune restoration in aging, T-cell differentiation support, and the program's broader claims of lifespan extension and reduced spontaneous carcinogenesis. The strongest citations are rodent longevity experiments from the Khavinson group reporting extended mean and maximum lifespan and reduced spontaneous tumor incidence in aged mice treated with KE, plus mechanistic work describing binding to DNA and regulation of gene expression in lymphocytes and other tissues. The honest caveats are substantial: essentially all of the supporting literature originates from the Khavinson research program and closely affiliated Russian laboratories, independent Western replication is scarce, there are no Western-standard randomized clinical trials for any indication, pharmacokinetic characterization in humans is absent, and the mechanism of direct DNA and histone binding by a dipeptide rests on molecular modeling that has not been reproduced outside the originating program. Vilon is sold as a peptide bioregulator in Russia (Peptides.ru / Khavinson Peptides capsule line) and elsewhere as a research chemical, not as a Western-approved medicine.

History & Discovery

Vilon emerged from the same Khavinson and Morozov program at the St. Petersburg Institute of Bioregulation and Gerontology that produced Thymalin, Thymagen, Epithalon, Livagen, and the rest of the short-peptide bioregulator catalog. Beginning in the 1970s, that group worked on fractionating low-molecular-weight calf-thymus preparations; by the late 1980s and 1990s they had isolated two principal active dipeptides from Thymalin — L-Glu-L-Trp (EW), developed as Thymagen / Thymogen, and L-Lys-L-Glu (KE), developed as Vilon. KE was then synthesized as a chemically defined peptide and studied as a minimal active fragment within the Thymalin framework. Vilon sits at an unusual point in the Khavinson catalog. It is more concretely defined than the parent Thymalin extract (a single synthesized dipeptide rather than a heterogeneous biological preparation) and it shares its N-terminal Lys-Glu motif with the tetrapeptide Livagen (KEDA), which the same group has used to argue for a sequence-level 'active core' logic across the broader bioregulator family. Despite this, Vilon has never achieved Western clinical adoption. Indexed Western literature is sparse, independent replication of the lifespan, anti-tumor, and chromatin-interaction claims is limited, and the dipeptide reaches Western users almost exclusively through the Khavinson Peptides oral capsule line and through research-chemical lyophilized vials.

How It Works

Vilon is a two-amino-acid peptide (lysine and glutamic acid) proposed to help restore immune function and regulate gene expression in aging cells. The Khavinson group describes it as one of the key active pieces of the Thymalin thymic complex, supporting T-cell maturation, dampening excessive inflammatory signaling, and — through a proposed interaction with DNA — reopening genes that get silenced with age.

Vilon (L-Lys-L-Glu, KE) is described in the Khavinson bioregulator literature as exerting its effects through several partly overlapping mechanisms. At the immune-cell level, it is reported to support T-cell differentiation and function, modulate cytokine balance, and — in combination with Thymagen as part of the Thymalin complex — reduce synthesis of pro-inflammatory cytokines including IL-1-beta, IL-6, and TNF-alpha in LPS-stimulated monocyte and COVID-19 cell models. In rodent lymphocytes and other aging tissues, KE has been reported to induce chromatin remodeling and activate transcription of previously silenced genes, an effect in the same family as that reported for the related tetrapeptide Livagen (KEDA). At the molecular level, the Khavinson group proposes that the KE dipeptide binds directly to DNA regulatory regions and to histone proteins, altering chromatin conformation and gene accessibility in a tissue-specific way. This model is supported by molecular-modeling and spectroscopic work from the originating program and has been invoked to explain the breadth of reported effects — immune restoration, reduced spontaneous carcinogenesis, and extended lifespan in aged rodents — but has not been independently replicated by non-affiliated laboratories. Vilon is also reported to modulate enkephalin-degrading enzyme activity and to affect proliferation and apoptosis balance in lymphoid tissue, consistent with a general neuroendocrine-immune regulatory role within the Khavinson framework.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vilon:

• 01Independent Western replication — essentially all efficacy data originates from the Khavinson research program at the St. Petersburg Institute of Bioregulation and Gerontology; independent reproduction by non-affiliated immunology or aging laboratories is limited.
• 02Western-standard human clinical trials — no published blinded randomized controlled trials of Vilon as a standalone agent for any indication exist in major Western clinical databases.
• 03Human pharmacokinetics — oral bioavailability of the Lys-Glu dipeptide, systemic exposure, half-life, and tissue distribution in humans are uncharacterized.
• 04Mechanism of direct DNA and histone binding — the molecular model that a dipeptide binds chromatin and modulates gene accessibility rests on molecular-docking and spectroscopic work from the originating program and has not been independently validated by Western structural biology.
• 05Long-term safety of repeated short courses — the canonical Khavinson 10-day-on / break schedule has not been evaluated for multi-year cumulative safety in any controlled setting.
• 06Lifespan and anti-carcinogenic claims — rodent longevity and reduced spontaneous tumor incidence data come from a single research program; independent replication in genetically diverse mouse cohorts has not been published.
• 07Differentiation between KE-specific effects and Thymalin-complex effects — much of the cited mechanistic work studies KE alongside EW or within Thymalin, making KE-specific attribution difficult.

Forms & Administration

Vilon is most commonly encountered in two forms: Russian Khavinson-line oral capsules (sold under Peptides.ru / Khavinson Peptides as a dietary supplement / functional food, typically a few hundred micrograms of peptide per capsule), and research-chemical lyophilized powder for subcutaneous or intramuscular injection sold outside Russia as 'not for human use.' Khavinson-style protocols typically involve short courses (roughly 10 days) repeated periodically rather than continuous use. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Common Questions

Who Vilon Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies for Vilon as a defined Lys-Glu dipeptide exist in the indexed literature. Theoretical considerations follow from the proposed immune-modulating mechanism rather than from documented clinical data. Concurrent use with intentional immunosuppression — calcineurin inhibitors, mTOR inhibitors, antimetabolites used in transplant medicine, biologic disease-modifying agents, and cytotoxic chemotherapy — could in principle interact with claimed T-cell-supportive activity in ways that are not predictable from preclinical data; clinician oversight is the only reasonable mitigation. Concurrent use with other Khavinson short peptides (Thymagen, Thymalin, Livagen, Epithalon) is common in the originating research framework, but no formal interaction or co-administration safety data exists outside the broader Thymalin literature. Bioregulator stacking in consumer practice frequently exceeds what the published evidence supports. Any concurrent prescription medication should be disclosed to the prescribing clinician before any Vilon use is considered.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions